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Abstract
Background: Two clinically relevant high-risk HPV (HR-HPV) types 16 and 18 are etiologically associated with the
development of cervical carcinoma and are also reported to be present in many other carcinomas in extra-genital
organ sites. Presence of HPV has been reported in breast carcinoma which is the second most common cancer in
India and is showing a fast rising trend in urban population. The two early genes E6 and E7 of HPV type 16 have
been shown to immortalize breast epithelial cells in vitro, but the role of HPV infection in breast carcinogenesis is
highly controversial. Present study has therefore been undertaken to analyze the prevalence of HPV infection in
both breast cancer tissues and blood samples from a large number of Indian women with breast cancer from
different geographic regions.
Methods: The presence of all mucosal HPVs and the most common high-risk HPV types 16 and 18 DNA was
detected by two different PCR methods - (i) conventional PCR assays using consensus primers (MY09/11, or GP5
+/GP6+) or HPV16 E6/E7 primers and (ii) highly sensitive Real-Time PCR. A total of 228 biopsies and corresponding
142 blood samples collected prospectively from 252 patients from four different regions of India with significant
socio-cultural, ethnic and demographic variations were tested.
Results: All biopsies and blood samples of breast cancer patients tested by PCR methods did not show positivity
for HPV DNA sequences in conventional PCRs either by MY09/11 or by GP5+/GP6+/HPV16 E6/E7 primers. Further
testing of these samples by real time PCR also failed to detect HPV DNA sequences.
Conclusions: Lack of detection of HPV DNA either in the tumor or in the blood DNA of breast cancer patients by
both conventional and real time PCR does not support a role of genital HPV in the pathogenesis of breast cancer
in Indian women.
Background
Breast cancer is the second most common cancer in the
world, after the cancer of the lung, affecting one in
eight women during their lifetime, but it is the leading
cancer among women worldwide [1]. In India breast
cancer is the second most dominant cancer in women,
but it is showing a fast rising trend in major metropoli-
tan cities in India [2]. Although various clinico-
epidemiologic, genetic and epigenetic factors including
mutations in breast cancer susceptibility genes BRCA1
and BRCA2 [3,4], sex-steroid hormones and lifestyle fac-
tors have been strongly implicated in the development
of breast cancer, the mechanism(s) of breast carcinogen-
esis is still not clearly understood.
High-risk human papillomaviruses (HR-HPVs) are
carcinogenic viruses which are primarily associated with
cervical cancer but are also linked with other anogenital
cancers and cancers of other organ sites [5] such as
oral cavity [6-8], esophagus [9-11], nasopharyngeal
and laryngeal carcinoma [5,12-15] and possibly in
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retinoblastoma [16-18]. In India, HPV is found to be
present in 100% of cervical cancer specimens and preva-
lence of high risk HPV type 16 is exceptionally high
(~90%) in them [19]. The HR-HPV oncoproteins E6 and
E7 which have been found to interact and inactivate the
two principal host cell tumor suppressor proteins p53
and Rb respectively [20-22] are also shown to immorta-
lize human mammary epithelial cells in-vitro [23,24].
Several other viruses have also been implicated in the
etiology of human breast cancer [23,24] but these are
not confirmed by other authors [25,26].
Reports on the distribution of HPV infection in breast
cancer are not only limited but also highly controversial.
Several authors [27-31] including our previous report on
fine needle aspirated breast cancer cells [32] did not
find any HPV infection in breast cancer. A moderate
frequency of 20-48% HPV infection was reported by
many authors [33-42], whereas a very high frequency of
HPV infection ranging from 60 to 85% occurrence of
HPV in breast cancer was reported by others [43-46].
Most interesting is recent demonstration of high risk
HPV18 in the breast cancer cell lines by in-situ hybridi-
zation and observation of HPV-specific koilocytes in
breast cancer cells which reiterates the oncogenic role
of HPV in breast cancer [47]. This prompted us to re-
look into the role of HPV in a large number of breast
cancer cases that were previously analyzed for mutations
in BRCA1, BRCA2 and p53 tumor suppressor genes [48]
and collected from all four different regions of India.
We used both conventional and real time PCR assays
with consensus (MY09/11, GP5+/GP6+) and type speci-
fic (HPV16 E6/E7) primers to detect HPV DNA
sequences in tumors as well as corresponding blood
samples of same breast cancer patients. The results
demonstrate complete absence of HPV DNA in breast
cancer patients in India.
Methods
Breast cancer patient population and sample collection
A total of two hundred fifty two breast cancer patients
(n = 252) were recruited for analysis of HPV infection
from different geographic regions of India. The region
wise distribution of samples is presented in Table 1.
Biopsies and blood samples were collected directly from
the surgical OT of respective hospitals (listed in
Table 1) in chilled phosphate-buffered saline and stored
at -70º C till further processing. 24 blood samples of
familial breast cancer cases collected (without biopsies)
from Goa, a distinct geographic region of India. The
majority of the cases were classified as infiltrating ductal
carcinoma. Written informed consent was obtained
from all the subjects included in the study and clinico-
epidemiological details were taken from their clinical
records. The study was approved by Institutional Ethics
Committee (IEC) of all the collaborating Institutes and
hospitals - Lok Nayak Hospital, New Delhi; Sher-I-
Kashmir Institute of Medical Sciences, Srinagar, Jammu &
Kashmir; Regional Institute of Medical Science, Imphal;
Assam Medical College, Dibrugarh; Silchar Medical
College, Silchar; Goa Medical College, Goa and Kidwai
Memorial Institute of Oncology, Bangalore in accordance
with the guidelines of Indian Council of Medical Research
(ICMR) and Helsinki Declaration. None of the breast
cancer patients had history of any other cancer or HPV
infection and all were inhabitants of India. The age of the
breast cancer patients recruited varied from 25-80 years,
the mean age being 51.5 ± 16.7.
DNA extraction for PCR
Cellular DNA from freshly collected breast tumor biop-
sies and peripheral venus blood were isolated using
standard Proteinase K digestion, phenol-chloroform
extraction and ethanol precipitation method routinely
being used in our laboratory [19,49,50]. The quality and
concentration of DNA was measured either on an
ethidium bromide-stained 1% agarose gel using Hind
III-digested lambda marker (Figure 1A) or by standard
spectrophotometric methods.
Conventional PCR using L1 consensus MY09/11 and GP5
+/GP6+ or HPV16 E6/E7 primers
Approximately, 100-200 hg cellular DNA was utilized
for conventional PCR using the protocol routinely fol-
lowed in our laboratory [48,49,51]. For the detection of
HPV DNA, both conventional as well as qRT-PCR
methodology were employed using most common L1
Table 1 Distribution of breast biopsies and blood samples from the different regions of India
Name of the Hospitals Biopsies Blood Matched biopsy
& blood
Lok Nayak Hospital, New Delhi 100 - -
Sher-I-Kashmir Institute of Medical Sciences, Srinagar, Jammu & Kashmir 43 43 43
Regional Institute of Medical Science, Imphal Assam Medical College, Dibrugarh Silchar Medical College, Silchar 65 65 65
Goa Medical College, Goa - 24 -
Kidwai Memorial Institute of Oncology, Bangalore 20 10 10
Total 228 142 118
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Figure 1 (A-D) Quantity and quality of genomic DNA from breast cancer biopsy and PCR amplification of different regions of HPV
genome. A: Estimation of quantity and quality of phenol-chloroform extracted genomic DNA from breast cancer biopsies as visualized on an
ethidium bromide-stained 1% agarose gel. Lane M: Hind III-digested l-DNA molecular weight marker. Lane 1-10: Genomic DNA samples from
breast cancer biopsies. B: PCR amplification of HPV L-1 consensus sequences showing the amplimer of 450 bp along with b-globin of 268 bp.
Lane M: Hae III-digested  × 174 DNA molecular weight marker. Lane 1: positive control (HPV16 plasmid DNA), Lane 2: HPV16 positive cervical
cancer biopsy DNA, Lane 3: Blood DNA from breast cancer patient, Lane 4: HPV negative cell line (C33a) DNA, Lane 5: MCF-7 cell DNA, Lane 6:
HeLa cell DNA, Lanes 7-18: breast cancer biopsy DNA. All were positive for b-globin but none of them positive for HPV. C: PCR amplification of
HPV16 E6 showing the amplimer of 503 bp along with b-globin of 268 bp. Lane M: Hae III-digested  × 174 DNA molecular weight marker.
Lane 1: positive control (HPV16 plasmid DNA), Lane 2: Cervical cancer DNA, Lane 3: Blood DNA from breast cancer patient, Lane 4: HPV negative
cell line (C33a) DNA, Lane 5: MCF-7 cell DNA, Lane 6: Human placental DNA, Lane 7:SiHa cell DNA, Lanes 8-18: breast cancer biopsy DNA
showing positivity for b-globin but negative for HPV. D: PCR amplification of HPV16 E7 showing the amplimer of 468 bp along with b-globin of
268 bp. Lane M: Hae III-digested  × 174 DNA molecular weight marker. Lane 1: positive control (HPV16 plasmid DNA), Lane 2: Cervical cancer
DNA, Lane 3: Blood DNA from breast cancer patient, Lane 4: HPV negative cell line (C33a) DNA, Lane 5: MCF-7 cell DNA, Lane 6: Human
placental DNA, Lane 7:SiHa cell line DNA, Lane 8-18: breast cancer biopsy DNA showing positivity for b-globin but negative for HPV.
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consensus primers (MY09/11, GP5+/GP6+) or type-
specific HPV16 E6/E7 primers. HPV16 plasmid DNA as
well as HPV16 positive tumor DNA from cervical can-
cer patients or HeLa DNA served as positive controls
whereas HPV negative cell line C33a DNA or human
placental DNA served as negative control. Amplification
of b- globin gene as well as exon 5 of p53 tumor sup-
pressor gene served as internal controls to examine
quality, integrity and successful amplification of breast
tissue DNA. Sequences of consensus primers (MY09/
MY11 and GP5+/GP6+) located within the conserved
L1 region of HPV genome, HPV16 E6 and E7 primers
along with b-globin and p53 of exon 5 primer sequences
are presented in Table- 2.
Briefly, the method involved a 25 μl reaction mix con-
taining 100-200hg DNA, 10 mM Tris-Cl (pH 8.4),
50 mM KCl, 1.5 mM MgCl2, 12.5 μM of each dNTP
(dATP, dCTP, dGTP and dTTP), 5 pmoles of each oli-
gonucleotide primer and 0.5 U Taq DNA polymerase
(Perkin-Elmer Biosystems, Foster City, CA, USA). The
temperature profile used for amplification constituted
an initial denaturation at 95°C for 5 min followed by 30
cycles with denaturation at 95°C for 30 sec, annealing at
55°C for 30 sec and extension at 72°C for 30 sec which
was extended for 7 min in the final cycle. The HPLC-
purified oligonucleotide primers were custom synthe-
sized commercially by M/s Microsynth GmbH (Balgach,
Switzerland).
qRT-PCR
Highly sensitive qRT-PCR was performed for detection
of low copy number HPV infection. qRT-PCR employed
in the study had the capability of detecting as low as 5
copies of HPV genome per reaction which is equivalent
to 0.005 HPV copies per cell equivalent using GP5
+/GP6+ consensus primers with Biorad SYBR Green
Supermix kit and iCycler PCR (Biorad, Hercules, CA).
p53 exon 5 primer sequences (Table 2) were used to
normalize the HPV DNA with respect to human geno-
mic DNA. qRT-PCR was calibrated using 10 fold serial
dilutions of HPV16 International Standards (IS; ranging
from 104-101) supplied under WHO Global HPV Lab-
Net program. Background genomic DNA from HPV-
negative cell line C33a was used as negative control and
for dilution of standards as prescribed by WHO. Briefly,
the amplification was performed in 25 μl reaction mix
containing 5 pmol each of GP5+ and GP6+ primers and
30-50hg of genomic DNA in 5 ul of test volume. The
amplification ramp included first step for 3 min at 95°C
for initial denaturation, followed by denaturation cycle
of 20 sec at 95°C, an annealing cycle of 15 sec at 40°C
and an elongation and readout cycle of 30 sec at 72°C
for 45 cycles. The specificity was verified by a dissocia-
tion curve analysis. Linear plots of the log copy number
vs the number of the threshold cycles was consistently
obtained for HPV16 L1 amplification and the correlation
coefficient was between 0.995 to 1.000 in each run.
Results
Of 252 patients studied, 62% were in pre-menopausal stage
while the remaining 38% formed the post-menopausal
group. Clinical staging showed 7.14% (18/252), 14.3%
(36/252), 23.01% (58/252), 23.8% (60/252), 26.6%
(67/252) and 5.15% (13/252) of the patients belonging
to stage I, IIa, IIb, IIIa, IIIb and IV respectively, whereas
histopathologic grading revealed 22.60% (57/252), 50.8%
(128/252) and 26.6% (67/252) of the tumors in grade I,
II and III respectively (Table 3). All the patients were of
Indian origin and inhabitants of either New Delhi,
North-East India region, southern India, Jammu &
Kashmir or Goa region. None of the patients showed
family history of any other cancer. DNA isolated from
Table 2 Oligonucleotide primer sequences used for the amplification of different regions of HPV and internal control
Primers Primer Sequences Location Annealing
temperature
(ºC)
Amplimer size
(bp)
Reference
MY09 5’-GCM CAG GGW CAT AAY AAT GG-3’ L1 55 450 [49]
MY11 5’-CGT CCM ARR GGA WAC TGA TC-3’ where M = A + C,
W = A + T, Y = C + T, R = A + G).
GP5+ 5’-TTT GTT ACT GTG GTA GAT ACT AC-3’ L1 40 145 [51]
GP6+ 5’-CTT ATA CTA AAT GTC AAA TAA AAA-3’
HPV16 E6 (F) 5’-GAA ACC GGT TAG TAT AAA AGC AGA C-3’ 53-78 55 503 [49]
HPV16 E6 (R) 5’-AGC TGG GTT TCT CTA CGT GTT CT-3’ 557-533
HPV16 E7 (F) 5’-CAA TAA TAT AAG GGG TCG GTG GA-3’ 480-500 55 468
HPV16 E7 (R) 5’-TTT TTC CAC TAC AGC CTC TAC AT-3’ 945-923 [49]
b-globin (F) 5’-GAA GAG CCA AGG ACA GGT AC-3’ 4-23 55 268 [49]
b-globin (R) 5’-CAA CTT CAT CCA CGT TAC ACC-3’ 273-256
p53 Exon 5 (F) 5’-TAC TCC CCT GCC CTC AAC AA-3’ 316-355 55 184 [48]
p53 Exon 5 (R) 5’-CAT CGC TAT CTG AGC AGC GC-3’ 499-480
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all the cases were employed for detection of HPV infec-
tion in biopsy and blood DNA using both conventional
as well as highly sensitive real-time PCR methods with
pre-calibrated WHO’s HPV16 international standards.
The tests were able to detect up to 5 HPV genome
equivalents per reaction i.e. 0.005 HPV copies per cell
equivalent. Human placental DNA or DNA derived
from HPV negative C33a cells, HPV18 positive HeLa
cells and DNA derived from HPV16 positive cervical
cancer biopsies were used as controls.
No HPV DNA was detected using consensus primers
located within the conserved L1 region of HPV genome by
performing 3 to 4 times repeated conventional PCR in any
of the 228 breast tumor and 142 blood DNA specimens,
while b-globin showed amplification of 268 bp product in
all the cases (Figure 1B). The repeat PCR of first PCR pro-
ducts also failed to detect any HPV DNA sequences.
When these tumor DNA samples were processed for
highly sensitive qRT-PCR, not a single sample was found
positive for the presence of HPV DNA (Figure 2A-D). We
again checked these samples with type-specific HPV16
E6/E7 primers, but all the samples were found negative for
any of HPV infections (Figure 1C &1D).
Discussion
Despite breast cancer being one of the most frequently
diagnosed cancers in women, the etiology and molecular
pathobiology of breast carcinogenesis is still not clearly
understood. In addition to various exogenous, endogen-
ous, hormonal and genetic risk factors responsible for
breast carcinogenesis, its viral etiology particularly impli-
cating HPV remains highly controversial. Although HPV
infection, particularly the HR-HPV types 16 and 18,
have been strongly implicated in the development of
cervical [52] and other cancers [53-63], the evidence for
an oncogenic role of HPV in breast cancer is limited.
Our previous study on a limited number of patients
[32] as well as several other reports worldwide [27-31]
did not observe any infection of HPV in breast cancer,
whereas a moderate (20-45%) to high frequency
(60-85%) of HPV infection has been reported by many
authors [33-42]. Recent reports of detection of very high
rate of HPV infection in breast cancer up to 85%
[43-46] and in breast cancer cell lines [47] prompted us
to re-look into the prevailing condition of HPV infection
in breast cancer which we refuted previously [32]. Since
in earlier study we used mainly fine needle aspirated
(FNAC) cells from breast cancer patients (n = 26)
including four tumor biopsy specimens to detect HPV,
in the present study we have screened as many as 228
sporadic breast cancer biopsy specimens and 142 blood
samples from a total of 252 breast cancer patients with
no history of HPV infection or HPV-associated malig-
nancies for the detection of HPV infection. The samples
were collected from four different geographic regions of
the country and two different PCR techniques both con-
ventional and highly sensitive qRT-PCR were employed.
The L1 consensus primers MY09/11 or GP5+/GP6+
and HPV16 E6/E7 (Table 2) which detect as may as 40
mucosal HPV genotypes, including the most prevalent
high risk (HPV 16 & 18) and low risk (HPV 6 & 11)
types were used but none of the samples by either
methods revealed presence of HPV DNA. Additionally,
blood samples from 24 familial breast cancer cases
which had defined hereditary etiology for development
of breast cancer failed to show presence of HPV DNA.
Of 22 previous studies on HPV in breast cancer till
date, 15 reported presence of HPV infection in breast
cancer and the authors have tried to put forward their
possible explanation for detection of HPV DNA in
breast cancer. Although the spreading of genital HPV
infection from one site to the other is not established, a
few studies have reported detection of genital HPVs in
peripheral blood lymphocytes of patients with urino-
genital cancers [64-67] and head & neck cancers [68].
So, it has been suggested that, there is a possibility of
systemic spread of oncogenic virus through organ perfu-
sion [69] facilitating its entry into the breast through
circulation. For this reason we tried to look for HPV
DNA in blood samples of 142 breast cancer patients
from Bangalore, North-east region, J & K and Goa but
none of them was found positive for HPV DNA. How-
ever, the detection of genital HPVs in the nipple and
areolar region reported by de Villers et al. [44] suggests
an alternative and perhaps more likely route of infec-
tion. Because of varied sexual behavior it is possible that
genital HPVs may transmit to breast through oro-genital
Table 3 Detailed pathological classification and clinical
stages of 252 breast cancer patients
Pathological classification Clinical
stages
Infiltrating Ductal Carcinoma (IDC) (218) Stage I (14)
Stage II (83)
Stage III (114)
Stage IV (7)
Mixed IDC & mucinous (20) Stage I (4)
Stage II (7)
Stage III (8)
Stage IV (1)
Medulllary Invasive carcinoma (8) Papillay invasive
carcinoma (6)
Stage II (4)
Stage III (5)
Stage IV (5)
IDC; Infiltrating ductal carcinoma.
Hedau et al. BMC Cancer 2011, 11:27
http://www.biomedcentral.com/1471-2407/11/27
Page 5 of 10
Figure 2 (A-D) Quantitative Real time PCR of HPV. Quantitative Real time PCR of GP5+/GP6+ to detect presence of HPV infection in
blood and tumour biopsy DNA from breast cancer patients. Genomic DNA isolated from blood and tumour tissue biopsies from breast
cancer patients were amplified using GP5+/GP6+ L1 consensus PCR primers using Biorad iQ SYBR Green supermix as described in Methods. Ten
fold dilution series of WHO HPV16 international standards in the 4 log dynamic range (5 × 104-100) in C33a DNA diluents were used as
reference for generation of standard curves. (A) DNA amplification; (B) Standard curve analysis showing efficiency of reaction and calculation of
viral copy number; (C) Melt curve analysis showing specificity of HPV16 amplicon and (D) Post real time PCR electrophoresis run of standards
and analyzed sample amplicons.
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route or directly through genital-breast contacts. So
there could be transmission of HPV infection by
mechanical path where the virus is scrubbed through
the skin [44]. However, the lack of detection of HPV in
breast cancer indicates that the virus has no role to play
in breast carcinogenesis in Indian women.
It is also interesting to note that several authors found
both positive and negative results from the same region
[27,29,43,44]. Studies showing positive as well as nega-
tive results for the presence of HPV infection in breast
cancer and benign breast tissues are listed in Tables 4
and 5. The reports that show different results from the
same country are also indicated. This could be due to
variable sexual practices, composition of study subject
and different HPV detection methods employed. de Vil-
liers et al [44] reported an extremely high positivity of
HPV DNA in 25 out of 29 samples (86%) in invasive
breast carcinoma and in 20 out of 29 samples (69%) of
the corresponding nipple samples collected from USA.
The most prevalent HPV genotypes detected in both
benign and breast tumors were HPV11 followed by
HPV6 which are low risk HPV-types that generally
cause benign lesions and warts and are non-oncogenic.
Only 12% cases were found to have infection of high
risk HPV type 16 but no HPV18 genotypes could be
detected. Bratthauer et al [27], in contrast, analyzed 43
cases of breast cancer from USA for the detection of
HPV DNA but surprisingly no HPV infection was
observed by these authors in breast cancer cases.
Similarly, from Austria, Widschwendter et al [43] ana-
lyzed only 11 cases of breast cancer, of which 7 (63.7%)
had HPV infection while Czerwenka et al [29] from the
same country reported complete absence of HPV infec-
tion in breast cancer cases. The reason(s) for disparity
of presence or absence of HPV infection in breast
cancer cases from the same country is not understood.
It may be primarily because of selection of primer types
and the amplicon region in the HPV genome which
could be the possible explanation for the observed dif-
ferences in HPV detection. It may also in part, be attrib-
uted to cross-contamination during collection and
processing of biological samples from other organ sites,
if infected with HPV.
Interestingly, in Brazilian women, Damin et al [38]
could not observe HPV DNA in benign breast disease,
but HPV could be detected in 25% of patients with
breast carcinoma. However, HPV infection was found to
have no correlation with prognosis of the disease. Lindel
and her colleagues [30] showed no evidence of HPV
infection in 81 Swiss women with breast carcinomas
using the SPF1/2 primers covering about 40 different
low, intermediate and high risk HPV types. Similarly, de
Cremoux et al [31] analyzed 50 invasive breast carci-
noma tissues from French patients using consensus and
type-specific primers but no HPV infection were
detected in any of breast cancer cases. Wrede et al [28]
analyzed a group of 95 British women with breast can-
cer for the infection of HPV6b, 11, 13, 16, 18, 30, 31,
32, 33, 45 and 51 but they also failed to detect any HPV
infection. Kroupis et al [45] performed HPV test on 107
breast carcinomas in Greece and only 17 (15.9%) were
found positive. Many of them were having multiple
infections of as many as 21 high risk HPV types and
majority (14/17; 67%) of them were positive for HPV16.
Table 4 List of studies identified HPV DNA sequences in breast cancer tissues
S. No. Study report Sample
size
Total
HPV
positivity
n (%)
HPV16
n (%)
HPV18
n (%)
HPV16/18
n (%)
Other HPV
types n (%)
Country
1 Di Lonardo et al., 1992 70 7 (10) 7 (100) 0 0 0 Italy
2 Henning et al., 1999 41 19(46.3) 19 (100) 0 0 0 Sweden
3. Yu et al., 1999 72 19(26.3) 0 0 0 19 (HPV 33) China
4. Yu et al., 2000 32 14(43.8) 0 0 0 14(HPV33) China
5. Liu et al., 2004 17 6(35) 3(50) 1(17) 0 0 China
6. Damin et al., 2004 101 25(24.7) 14(56) 10(40) 1(4) 0 Brazil
7. Widschwendter et al., 2004 11 7(63.7) 7(100) 0 0 0 Austria*
8. de Villiers et al., 2005 29 25(86.2) 3(12) 0 0 22(88) USA*
9. Kroupis et al., 2006 107 17(15.9) 14(82.3) 0 0 3(17.6) Greece
10. Kan et al., 2005 50 24(48) 0 24(100) 0 0 Australia
11. Gumus et al., 2006 50 37(74) 0 20(54) 0 35(94.6) Turkey
12. Khan et al., 2008 124 26(20.9) 26(100) 0 0 0 Japan
13. de Leon et al., 2009 51 15(29.5) 10(66.7) 3(20) 2(13.3) 0 Mexico
14. Mendizabal-Ruiz et al., 2009 67 3(4) 1(33.3) 1(33.3) 0 1(33.3) Mexico
15. Heng et al., 2009 26 biopsies 8 (30.7) 1 (3.8) 7 (26.9) 0 0 Australia
9 cell lines 2 (22) 0 2 (22) 0 0
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Yu et al [35] analyzed 72 patients from Shanghai, China
and Tokushima in Japan found 34.1% positivity for
HPV33 alone but there was no evidence of HPV16-
positive breast cancer. Yet another study by Mendiza-
bal-Ruiz et al [41] analyzed 67 breast cancer patients
including 40 non-malignant tissues and a very low 4.4%
(3/67) frequency of HPV infection was observed.
Although there exists conflicting reports, it does not
insinuate that the reports that did not find viruses in
breast cancer specimens were attempting to confirm or
refute previous reports but failed to detect HPV. How-
ever, it is also clear from these studies that presence of
HPV infection in breast cancer may not be a universal
phenomenon. The prevalence of HPV infection in breast
cancer may differ between places and population and
several factors may contribute to this effect. This is
amply clear from a recent interesting study of Heng
et al [47] who analyzed HPV DNA sequences in as
many as nine human breast cancer cell lines including
the commonly used MCF-7 cells but only two cell lines
(MDA-MB-175 VII and SK-BR-3) were found positive
for HPV18. It is, however, not unlikely that these two
breast cancer cell lines might have got contaminated in
the laboratory with most commonly used HeLa cells
that harbor HPV18.
Several other authors from different parts of the world
reported presence of HPV infection in breast cancer
cases. It is, however, most important to note that not
many studies have indicated or analyzed if the women
with breast cancer recruited for HPV detection also had
anogenital or oropharynheal lesions with HPV infection.
Although the route of HPV transmission from one
organ to the other is not clear, Hening et al [34]
demonstrated HPV16 in 46% of breast carcinoma
patients who had a history of CIN III lesions. Most
interestingly, all patients with HPV16 positive for breast
cancer correspond to same patients with cervical CIN
III lesions with HPV16 infection. This is indicative of
possible transmission of virus from ano-genital organs
to the breast. One of the route discussed earlier could
be through blood circulation [64-68]. So, it is essential
to look for genital or oropharyngeal infection of HPV in
breast cancer patients to rule out the possibility of inter-
organ transmission and/or cross contamination of viral
infection. However, published data suggest that various
epidemiological factors, sexual behavior including the
history of HPV-associated diseases specific to the region
may play a role in differential distribution of HPV in
breast cancer [30].
In spite of exceedingly higher prevalence of genital
HPV infection in India as compared to that in Europe
and in the USA including presence of other conducive
risk factors such as early age marriage, multiple preg-
nancy, malnutrition, poor hygiene and healthcare, the
complete absence of HPV infection in Indian women
with breast cancer in the present study does not suggest
the role of HPV in breast carcinogenesis in Indian
women. It is suggested that although HPV DNA is
undetectable, serologic assay may be useful in revealing
exposure by detecting presence of antibodies against
HPV. But natural HPV infection being poorly immuno-
genic, the antibody titer will be too low to be detected
with the existing serological tests. HPV serology is
presently not available in our laboratory and is being
developed under the WHO LabNet programme. We
however, do not preclude the possibility of yet unidenti-
fied HPV playing important role in breast carcinogenesis
in India. Furthermore, due to the changing social and
psyco-sexual behavior particularly in urban Indian popu-
lation, it may not be unlikely to find, presence of HPV
in breast tissue in future due to an exterior transfer of
HPV form genital organs to the breast.
Conclusions
Complete absence of HPV DNA either in the tumor tis-
sue or in the blood of the same breast cancer patients
recruited from four different regions of the country by
employing the highly sensitive qRT-PCR does not sup-
port the etiological role of oncogenic HPV in the patho-
genesis of breast cancer in Indian women.
Table 5 List of studies that did not detect HPV DNA sequences in breast cancer tissues
S. No Study report Sample
size
Total HPV
positivity
n (%)
HPV16
n (%)
HPV18
n (%)
HPV16/18
n (%)
Other HPV
types n (%)
Country
1 Wrede et al., 1992 92 0 0 0 0 0 UK
2 Bratthauer et al., 1992 43 0 0 0 0 0 USA*
3. Gopalkrishna et al., 1996 30 0 0 0 0 0 India
4. Czerwenka et al., 1996 20 0 0 0 0 0 Austria*
5. Lindel et al., 2007 81 0 0 0 0 0 Switzerland
6. de Cremoux et al., 2008 50 0 0 0 0 0 France
7. Hedau et al. (Present study) 252* 0 0 0 0 0 India
* Country with both positive and negative results.
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